User Experiences of Pharmacogenomic Testing and Opinions among Psychiatry Patients
Journal of Personalized Medicine · 23.12.2023 · 14 (1) · 22
DOI: 10.3390/jpm14010022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 23.12.2023. Verfasst von Catherine R Virelli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M6J 1H4,…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Larry and Judy Tanenbaum Family Foundation.
Abstract (Originalsprache)
Pharmacogenomic testing (PGx) is a tool used to guide physicians in selecting an optimal medication for clients based on their genetic profile. The objective of this qualitative study is to understand patients’ experiences with PGx testing as well as their opinions regarding the clinical adoption of such tests in psychiatry. A focus group was conducted to assess the needs of clients who had experience using a PGx test. Participants were recruited from a large study on PGx testing that offered physicians an opportunity to use PGx reports to guide psychotropic prescriptions. The focus group discussions were recorded, transcribed, and coded using NVivo to identify core themes. A total of 11 people participated in the focus group. Our analysis revealed that many participants were in favour of implementing PGx testing in psychiatric practice, and all expressed important considerations for patient-centred optimization of PGx testing. The main themes captured were: education and awareness among clinicians, cost considerations, PGx results-sharing and accessibility, and prospective benefits. The results of this study suggest that patients are keen to see PGx testing in widespread clinical care, but they report important opportunities to improve knowledge mobilization of PGx testing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M6J 1H4, Canada.
- Translational Research Program, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Department of Neurology, Columbia University, New York, NY 10027, USA.
- Department of Psychiatry, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Förderung
- The Larry and Judy Tanenbaum Family Foundation
Zitieren
APA
Virelli, C. R., Ebrahimi, M., Mohiuddin, A. G., Tomasi, J., Lisoway, A. J., Herbert, D., Marshe, V. S., Kidd, S. A., Ferenbok, J., & Kennedy, J. L. (2023). User Experiences of Pharmacogenomic Testing and Opinions among Psychiatry Patients. Journal of Personalized Medicine, 14(1), 22. https://doi.org/10.3390/jpm14010022
Vancouver
Virelli CR, Ebrahimi M, Mohiuddin AG, Tomasi J, Lisoway AJ, Herbert D, et al. User Experiences of Pharmacogenomic Testing and Opinions among Psychiatry Patients. Journal of Personalized Medicine. 2023;14(1):22. doi:10.3390/jpm14010022
BibTeX
@article{Virelli2023,
author = {Virelli, Catherine R and Ebrahimi, Mahbod and Mohiuddin, Ayeshah G and Tomasi, Julia and Lisoway, Amanda J and Herbert, Deanna and Marshe, Victoria S and Kidd, Sean A and Ferenbok, Joseph and Kennedy, James L},
title = {User Experiences of Pharmacogenomic Testing and Opinions among Psychiatry Patients},
journal = {Journal of Personalized Medicine},
year = {2023},
volume = {14},
number = {1},
pages = {22},
doi = {10.3390/jpm14010022}
}
EUVIMED